Decision: Favourable
Study Title:
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508deland a Minimal Function Mutation (F/MF)
NREC Code:
21-NREC-CT-101
Decision:
Favourable
Meeting Date:
06/10/2021
Study Type:
CT application
Principal Investigator:
Prof. Edward McKone
PI Institution:
St Vincent's University Hospital
Sponsor:
Vertex Pharmaceuticals